Cargando…
Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
| Autores principales: | , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8257476/ https://www.ncbi.nlm.nih.gov/pubmed/33483617 http://dx.doi.org/10.1038/s41375-021-01125-4 |
| _version_ | 1783718322617974784 |
|---|---|
| author | Sekeres, Mikkael A. Watts, Justin Radinoff, Atanas Sangerman, Montserrat Arnan Cerrano, Marco Lopez, Patricia Font Zeidner, Joshua F. Campelo, Maria Diez Graux, Carlos Liesveld, Jane Selleslag, Dominik Tzvetkov, Nikolay Fram, Robert J. Zhao, Dan Bell, Jill Friedlander, Sharon Faller, Douglas V. Adès, Lionel |
| author_facet | Sekeres, Mikkael A. Watts, Justin Radinoff, Atanas Sangerman, Montserrat Arnan Cerrano, Marco Lopez, Patricia Font Zeidner, Joshua F. Campelo, Maria Diez Graux, Carlos Liesveld, Jane Selleslag, Dominik Tzvetkov, Nikolay Fram, Robert J. Zhao, Dan Bell, Jill Friedlander, Sharon Faller, Douglas V. Adès, Lionel |
| author_sort | Sekeres, Mikkael A. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8257476 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-82574762021-07-23 Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML Sekeres, Mikkael A. Watts, Justin Radinoff, Atanas Sangerman, Montserrat Arnan Cerrano, Marco Lopez, Patricia Font Zeidner, Joshua F. Campelo, Maria Diez Graux, Carlos Liesveld, Jane Selleslag, Dominik Tzvetkov, Nikolay Fram, Robert J. Zhao, Dan Bell, Jill Friedlander, Sharon Faller, Douglas V. Adès, Lionel Leukemia Letter Nature Publishing Group UK 2021-01-22 2021 /pmc/articles/PMC8257476/ /pubmed/33483617 http://dx.doi.org/10.1038/s41375-021-01125-4 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Letter Sekeres, Mikkael A. Watts, Justin Radinoff, Atanas Sangerman, Montserrat Arnan Cerrano, Marco Lopez, Patricia Font Zeidner, Joshua F. Campelo, Maria Diez Graux, Carlos Liesveld, Jane Selleslag, Dominik Tzvetkov, Nikolay Fram, Robert J. Zhao, Dan Bell, Jill Friedlander, Sharon Faller, Douglas V. Adès, Lionel Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML |
| title | Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML |
| title_full | Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML |
| title_fullStr | Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML |
| title_full_unstemmed | Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML |
| title_short | Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML |
| title_sort | randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk mds/cmml or low-blast aml |
| topic | Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8257476/ https://www.ncbi.nlm.nih.gov/pubmed/33483617 http://dx.doi.org/10.1038/s41375-021-01125-4 |
| work_keys_str_mv | AT sekeresmikkaela randomizedphase2trialofpevonedistatplusazacitidineversusazacitidineforhigherriskmdscmmlorlowblastaml AT wattsjustin randomizedphase2trialofpevonedistatplusazacitidineversusazacitidineforhigherriskmdscmmlorlowblastaml AT radinoffatanas randomizedphase2trialofpevonedistatplusazacitidineversusazacitidineforhigherriskmdscmmlorlowblastaml AT sangermanmontserratarnan randomizedphase2trialofpevonedistatplusazacitidineversusazacitidineforhigherriskmdscmmlorlowblastaml AT cerranomarco randomizedphase2trialofpevonedistatplusazacitidineversusazacitidineforhigherriskmdscmmlorlowblastaml AT lopezpatriciafont randomizedphase2trialofpevonedistatplusazacitidineversusazacitidineforhigherriskmdscmmlorlowblastaml AT zeidnerjoshuaf randomizedphase2trialofpevonedistatplusazacitidineversusazacitidineforhigherriskmdscmmlorlowblastaml AT campelomariadiez randomizedphase2trialofpevonedistatplusazacitidineversusazacitidineforhigherriskmdscmmlorlowblastaml AT grauxcarlos randomizedphase2trialofpevonedistatplusazacitidineversusazacitidineforhigherriskmdscmmlorlowblastaml AT liesveldjane randomizedphase2trialofpevonedistatplusazacitidineversusazacitidineforhigherriskmdscmmlorlowblastaml AT selleslagdominik randomizedphase2trialofpevonedistatplusazacitidineversusazacitidineforhigherriskmdscmmlorlowblastaml AT tzvetkovnikolay randomizedphase2trialofpevonedistatplusazacitidineversusazacitidineforhigherriskmdscmmlorlowblastaml AT framrobertj randomizedphase2trialofpevonedistatplusazacitidineversusazacitidineforhigherriskmdscmmlorlowblastaml AT zhaodan randomizedphase2trialofpevonedistatplusazacitidineversusazacitidineforhigherriskmdscmmlorlowblastaml AT belljill randomizedphase2trialofpevonedistatplusazacitidineversusazacitidineforhigherriskmdscmmlorlowblastaml AT friedlandersharon randomizedphase2trialofpevonedistatplusazacitidineversusazacitidineforhigherriskmdscmmlorlowblastaml AT fallerdouglasv randomizedphase2trialofpevonedistatplusazacitidineversusazacitidineforhigherriskmdscmmlorlowblastaml AT adeslionel randomizedphase2trialofpevonedistatplusazacitidineversusazacitidineforhigherriskmdscmmlorlowblastaml |